Stockhub

CombiGene AB: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 August 2022

  • curprev 05:4205:42, 16 August 2022 >Paris 759 bytes +759 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develo..."
Retrieved from "https://stockhub.co/research/CombiGene_AB"